Search
Displaying 241–250 of 693 for “retinal diseases”
-
VISIONS 2014 — My Retina Tracker: Track Your Vision and Drive the Research
Research NewsThe powerful and secure system enables patients to keep track of their clinical care and vision changes. At the same time, it enables scientists to search the “de-identified” (i.e., anonymous) patient information to study conditions and identify targets for treatments, preventions and cures.
-
Proving a Vision-Saving Treatment Works
Research NewsThe information gleaned from ProgSTAR will be of enormous value in designing future clinical trials for Stargardt disease treatments.
-
Curing Blindness, Part 2: Dick’s Story
Beacon StoriesStem-cell-based therapies – including those derived from a patient’s blood or skin – are among the many cutting-edge approaches to treatments the Foundation has funded for decades.
-
Curing Blindness, Part 1: Corey’s Story
Beacon StoriesHow gene therapy restored some of a boy’s sight.
-
Opus Genetics Secures $155 Million Financing to Accelerate Gene Therapy Pipeline
Research NewsStrategic funding extends cash runway through 2029 and advances multiple inherited retinal disease programs
-
Sumitomo Pharma Receives FDA Orphan Drug Designation for Retinitis Pigmentosa Treatment
Research NewsPotential cell therapy, DSP-3077, gains special regulatory status to support development for inherited retinal disease.
-
SparingVision Completes Dosing in Gene-Agnostic Therapy Trial for Retinitis Pigmentosa (RP)
Research NewsNovel neuroprotective approach could benefit RP patients regardless of genetic mutation
-
A Family United: Thomas’ Hero’s Journey with CRB1
Beacon StoriesWhen Becky’s son Thomas was diagnosed with a rare CRB1-associated disease, their family’s world changed. But today, Becky and Thomas are embracing advocacy, community, and research as they work to raise awareness and fuel progress toward treatments and cures.
-
Advocacy Research News
In this in-depth interview hosted by InVivo, Jason Menzo, CEO of the Foundation Fighting Blindness, outlines the organization’s strategy for addressing significant changes and opportunities in the inherited retinal diseases (IRDs).
